Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898131|
Recruitment Status : Recruiting
First Posted : May 12, 2009
Last Update Posted : November 24, 2017
RATIONALE: Collecting and storing samples of tumor tissue from patients with breast cancer to study in the laboratory may help doctors learn more about cancer.
PURPOSE: This phase I study is collecting tissue samples for future research from women undergoing surgery for breast cancer.
|Condition or disease|
- Collect breast tissue for future research from women undergoing surgery for breast cancer.
- Create microarrays by tumor type for internal use by Specialized Program of Research Excellence.
OUTLINE: Tumor tissue is collected and analyzed to create microarrays by tumor type for future research studies.
PROJECTED ACCRUAL: A total of 1,250 patients will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Specialized Program of Research Excellence (SPORE) in Breast Cancer: Tissue and Specimen Collection|
|Study Start Date :||August 2001|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
- Collect human breast tissues and associated clinical-pathologic data [ Time Frame: At time of diagnosis, surgery, and throughout standard care and clinical follow-up. ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898131
|Contact: Seema Khan, MDemail@example.com|
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University||Recruiting|
|Chicago, Illinois, United States, 60611-3013|
|Contact: Clinical Trials Office - Robert H. Lurie Comprehensive Cancer 312-695-1301 firstname.lastname@example.org|
|Principal Investigator:||Piotr Kulesza, MD, PhD||Northwestern University|